-1752956575380.webp&w=3840&q=75)
2025 NOSCM | Pancreas, Hepatic and Cholangiocarcinoma: Advances in 2025
0% Complete
Course Overview
Dr. Caio Max Rocha-Lima reviewed 2025 advances in pancreatic, hepatic, and cholangiocarcinoma care. Pre-op therapies showed improved survival, with Pax G outperforming FOLFIRINOX in the Cassandra trial. Panova 3 spotlighted a survival-boosting device. NCCN now backs neoadjuvant care for all risk groups.
Course Content
Course Details
- Duration
- 0.00 hour
- Released
- Jul 20, 2025
- Last Review
- Jul 20, 2025
- Expires
- Jul 20, 2026
Objectives
NA
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
Faculty & Disclosure
Faculty
Caio Max Rocha-Lima, MD, MS
Disclosure
<p>NA</p>
Accreditation
NA
-1773064516362.webp&w=3840&q=75)
-1773063846465.webp&w=3840&q=75)